Side-by-side · Research reference

GDF-8vsVilon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED23/48 cited

BAnimal-StrongHUMAN-REVIEWED13/49 cited

GDF-8

TGF-β Superfamily · Negative Muscle Regulator

15–20%Muscle mass gain (MSTN−/−)

↓ AdiposityFat reduction (loss-of-function)Herman 2026 Jacquez 2026

No adversePhenotype (genetic null)Jacquez 2026

Not administered — research target for inhibition

Vilon

Khavinson Bioregulator · Dipeptide

2 AADipeptide

T-helperStimulatesLinkova 2011

MouseModel basisKhavinson 2002

Literature lacks standardised clinical route

01Mechanism of Action

Parameter

GDF-8

Vilon

Primary target

Activin type II receptors (ActRIIA/B) on skeletal muscleIglesias 2026

Immune cell differentiation pathways, chromatin modification

Pathway

MSTN → ActRII/TGFBR1 → Smad2/3 signaling → muscle protein synthesis suppression

Vilon → Thymocyte sphingomyelinase activation → T-helper & cytotoxic T-cell differentiation; epigenetic suppression of aging markers (CCL11, HMGB1)

Downstream effect

Restricts muscle hypertrophy, limits satellite cell activation, increases proteolysis via ubiquitin-proteasome and autophagy pathwaysGong 2026 Iglesias 2026

Enhanced T-cell differentiation (CD4+, CD8+, B-cells), thymocyte proliferation, modulated IL-1β comitogenic activity, proposed chromatin decondensation in aged lymphocytesLinkova 2011 Khavinson 2002 Lezhava 2023

Feedback intact?

Yes — part of muscle-pituitary endocrine axis; muscle-derived MSTN influences FSH synthesisIglesias 2026

Unknown — no HPA/HPG axis data

Origin

Endogenous myokine secreted by skeletal muscle; circulates systemically as latent complexIglesias 2026

Synthetic dipeptide derived from Khavinson thymic peptide extraction studies (Thymalin fraction)Morozov 1997

Antibody development

—

02Dosage Protocols

Parameter

GDF-8

Vilon

Clinical use

None — MSTN is a research target for inhibition, not a therapeutic peptide administered to humans

Sold by research suppliers (e.g., CertaPeptides) for in vitro / animal studies only.

—

Inhibition strategies

Monoclonal antibodies, VLP-based active immunotherapy, gene editing (CRISPR)

—

VLP immunogen (MS2.87-97)

Active immunization protocol in mice — elicits anti-MSTN antibodies without GDF11 cross-reactivityJacquez 2026

Reduces body fat, increases muscle mass and grip strength; no major safety concerns in animal models.Jacquez 2026

—

Dual immunization (MSTN + Activin A)

Combined active immunization in GH-deficient miceMansoor 2026

Improves skeletal muscle performance beyond single-target inhibition.Mansoor 2026

—

Gene editing outcomes

Precision CRISPR edits produce double-muscle phenotype, improved carcass quality in livestock

Pleiotropic effects on metabolism, reproduction, and welfare require systematic evaluation.

—

Standard dose

—

No clinical standard — literature lacks human dosing

Russian practice: often combined with other Khavinson peptides; no FDA/EMA trials.

Animal model dose

—

In vitro: 0.01–10 μg/mL culture medium (mouse thymocytes)

Not translatable to human mg/kg without pharmacokinetic data.

Frequency

—

Unknown — literature does not specify chronic administration protocols

Evidence basis

—

Mouse / in vitro only

Duration

—

Not characterised in humans

Route

—

Likely SQ or oral (Khavinson school uses both); no published ROA validation

Half-life

—

Not published — dipeptides typically <10 min plasma t½

03Metabolic / Fat Loss Evidence

Parameter

GDF-8

Vilon

Primary mechanism

MSTN loss-of-function reduces fat accumulation independent of muscle mass effects

—

Human genetic evidence

Humans with MSTN function-disrupting variants have increased muscle mass, strength, and reduced adiposityHerman 2026

—

Animal model outcomes

VLP-immunized mice: reduced age-associated weight gain, significantly lower body fat by DEXAJacquez 2026

—

Adipose-muscle crosstalk

MSTN modulates myostatin-TAZ signaling; inhibition shifts adipose expansion toward hyperplasiaLi 2026

—

Metabolic benefits

Improved metabolic health in genetic MSTN null modelsJacquez 2026

—

Age-related effects

MSTN upregulation linked to age-dependent muscle atrophy and fat accumulation

—

04Side Effects & Safety

Parameter

GDF-8

Vilon

Genetic null phenotype

No known adverse phenotypes in humans or mice with MSTN loss-of-functionJacquez 2026

—

Antibody cross-reactivity risk

Non-selective inhibitors may block GDF11, affecting cardiac and neural function

—

VLP immunotherapy safety

No major safety concerns in mice; rare hypersensitivity possibleJacquez 2026

—

Echocardiography

No cardiac abnormalities detected in MSTN-immunized miceJacquez 2026

—

Pleiotropic effects (gene editing)

MSTN editing may affect reproductive performance, metabolic homeostasis, and animal welfare

—

Assay variability

Circulating MSTN levels often fail to mirror intramuscular changes; clinical interpretation challengingIglesias 2026

—

Human safety data

—

Absent from PubMed-indexed literature

Theoretical risk

—

Immune hyperactivation in autoimmune-prone individuals (T-cell differentiation enhancement)

Antibody formation

—

Not reported; dipeptides generally low immunogenicity

Animal models

—

No adverse effects noted in mouse thymocyte or pineal lymphoid cultures

Absolute Contraindications

GDF-8

·Not applicable — MSTN is not administered as a therapeutic agent

Vilon

·Active autoimmune disease (theoretical — no clinical data)

Relative Contraindications

GDF-8

·Inhibition strategies contraindicated in conditions requiring maintained muscle proteostasis (theoretical)

Vilon

·Pregnancy / lactation (no safety data)
·Acute infection with cytokine storm risk (immune modulation unknown)

05Administration Protocol

Parameter

GDF-8

Vilon

1. Research context only

GDF-8 (myostatin) is not administered to humans. It is studied as a target for inhibition using monoclonal antibodies, active immunotherapy (VLP-based vaccines), or gene editing (CRISPR). Research-grade peptide supplied by vendors like CertaPeptides is intended for in vitro and animal studies only.

No clinical protocols exist in Western peer-reviewed literature. Russian gerontological practice may use 1–10 mg ranges, but dosing is empirical.

2. Inhibition strategies

Clinical development focuses on blocking MSTN activity via: (1) neutralizing monoclonal antibodies targeting mature MSTN or ActRII receptors; (2) active immunotherapy generating endogenous anti-MSTN antibodies (e.g., MS2.87-97 VLP platform); (3) precision gene editing to disrupt MSTN expression in livestock or therapeutic contexts.

Subcutaneous injection (common for Khavinson peptides) or oral (some bioregulators reportedly active orally due to small size). No validated ROA.

3. VLP immunization protocol (animal model)

MS2.87-97 VLP administered to mice elicits anti-MSTN antibodies targeting a discrete epitope in mature MSTN protein. Immunization schedule and dose optimized for sustained antibody response without GDF11 cross-reactivity. No human protocols established.Jacquez 2026

Unknown — no circadian or meal-timing data. Khavinson school often recommends morning administration.

4. Gene editing considerations

CRISPR-mediated MSTN knockout produces double-muscle phenotype in livestock (cattle, swine, sheep). Ethical frameworks and welfare assessments required; pleiotropic effects on reproduction, metabolism, and health must be systematically evaluated before human translation.

Likely lyophilised powder, refrigerated. Reconstitution protocols not published.

06Stack Synergy

GDF-8

— no documented stacks

Vilon

+ Epitalon

Moderate

View Epitalon →

Both are Khavinson bioregulators targeting aging pathways. Epitalon (Ala-Glu-Asp-Gly) acts on telomerase and pineal function; Vilon on immune differentiation and chromatin decondensation. Combined in Russian gerontological protocols for multi-system aging intervention. Lezhava et al. (2023) tested both on aged lymphocyte chromatin, showing distinct epigenetic effects. Complementary, not synergistic in strict pharmacological sense.

Vilon: Empirical — no standard
Epitalon: Empirical — often 10 mg cycles
Frequency: Sequential or concurrent (literature ambiguous)
Primary benefit: Multi-system aging modulation (immune + pineal/circadian)

+ Thymalin

Weak

View Thymalin →

Thymalin is the parent polypeptide complex from which Vilon was isolated. Both target immune differentiation, but Thymalin is a complex mixture (multiple peptides), whereas Vilon is a purified dipeptide. Morozov & Khavinson (1997) described Vilon as a synthetic successor designed to replicate Thymalin's immunomodulatory effects with greater specificity. Redundant in practice; no published combination studies.

Vilon: No standard
Thymalin: 10–100 mg IM (polypeptide complex)
Primary benefit: Redundant — both target T-cell differentiation

Morozov 1997 Khavinson 2020